首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 抗體和免疫 > 全球單株抗體市場(到2017年為止):針對腫瘤和自體免疫症，多重適應症的認證與單株抗體市場的潛在力的市場重組
產業/市場分類
生物科技 (1574)
分子標靶治療學 (131)
生技設備 (354)
生物材料 (53)
生物標記 (155)
以基因為基之藥物開發 (202)
再生醫學 (119)
抗體和免疫 (189)
個人化醫學 (51)
基因治療學和RNAi (102)
市場調查報告書

全球單株抗體市場(到2017年為止):針對腫瘤和自體免疫症，多重適應症的認證與單株抗體市場的潛在力的市場重組

Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market

出版商 GBI Research
出版日期 2011年12月 商品編碼 224312
內容資訊 英文 Pages: 172
價格
US $ 3500 PDF by E-mail (Single user license)
US $ 7000 PDF by E-mail (Site license)
US $ 10500 PDF by E-mail (Global license)


全球單株抗體市場(到2017年為止):針對腫瘤和自體免疫症，多重適應症的認證與單株抗體市場的潛在力的市場重組 是由出版商GBI Research在2011年12月所出版的。 這份英文市場調查報告書包含Pages: 172 價格從美金3500起跳。

簡介

單株抗體的全球市場2002-2010年以年平均36.7％成長，2010年達到156億美元的規模。2010-2017年的年平均市場成長率為10.6％，2017年的市場規模預計將達到317億美元。

本報告提供單株抗體的全球市場的最新趨勢與未來展望相關分析，整體市場結構與趨勢，及主要的不同疾病的市場趨勢及上市產品·臨床實驗·有潛力的分子資訊，再加上主要企業簡介，企業間的合作·資本交易趨勢等內容，為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 市場特徵

  • 簡介
  • 單株抗體技術
  • 收益預測:全球(處方人口，治療費，收益)
  • 收益預測:各國(美國·歐洲·其他)
  • 治療方法的利用模式(美國·歐洲·其他)
  • 年度治療費用(美國·歐洲·其他)
  • 全球單株抗體的趨勢(市場·技術)
  • 企劃趨勢
  • 全球單株抗體市場推動因素
  • 全球單株抗體市場阻礙因素
  • 未滿足需求

第4章 乳癌(免疫疾病增強劑與轉移)

  • 概要
  • 簡介
  • 處方人口(全球·各國)
  • 年度治療費用(全球·各國)
  • 市場規模(全球·各國)
  • 市售產品
    • Herceptin (trastuzumab)
  • 開發平台分析
  • 有潛力的分子
    • Pertuzumab (2C4，商標名「Omnitarg」)
    • Ramucirumab (IMC-1121B)

第5章 伴隨癌症治療的骨轉移·骨質流失的單株抗體的市場規模

  • 簡介
  • 免疫學
  • 診斷
  • 治療
  • 處方人口(全球·各國)
  • 年度治療費用(全球·各國)
  • 市場規模(全球·各國)
  • 市售產品
    • Xgeva (denosumab)
  • 開發平台分析

第6章 復發型多發性硬化症(RRMS)的單株抗體的市場規模

  • 簡介
  • 免疫學
  • 診斷
  • 治療
  • 處方人口(全球·各國)
  • 年度治療費用(全球·各國)
  • 市場規模(全球·各國)
  • 市售產品
  • 開發平台分析
  • 有潛力的分子
    • Campath (Alemtuzumab)
    • Ocrelizumab

第7章 轉移性非小細胞肺癌(NSCLC)的單株抗體的市場規模

  • 簡介
  • 免疫學
  • 診斷
  • 處方人口(全球·各國)
  • 年度治療費用(全球·各國)
  • 市場規模(全球·各國)
  • 市售產品
    • Avastin
  • 開發平台分析
  • 有潛力的分子
    • Necitimumab
    • Ramucirumab

第8章 類風濕性關節炎

  • 簡介
  • 免疫學
  • 診斷
  • 治療
  • 處方人口(全球·各國)
  • 年度治療費用(全球·各國)
  • 市場規模(全球·各國)
  • 市售產品
    • Rituxan
    • Remicade
    • Humira
    • Cimzia
    • Simponi
    • Actemra
  • 開發平台分析
  • 有潛力的分子
    • Ofatumumab (Arzerra)
    • SAR153191(REGN88)

第9章 競爭環境

  • 市場佔有率分析
  • Amgen Inc.
  • Abbott Laboratories
  • Johnson & Johnson
  • Novartis AG
  • Biogen Idec
  • Merck & Co. Inc.
  • Eli Lilly and Company
  • Roche

第10章 策略性企業整合

  • 交易的種類
  • 企業合併·收購
  • 授權合約
  • 夥伴關係

第11章 附錄

圖表一覽

目錄

Abstract

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market” which provides insights about monoclonal antibodies sales forecasts until 2017. Monoclonal antibodies markets in the key geographies of the US, Europe and the Rest of The World are also covered in the report. The report also includes details about monoclonal antibodies R&D pipelines and potential future blockbuster products. The report provides in-depth analysis of therapeutic indication, which includes HER2 Breast Cancer, Bone Metastases and Bone Loss Due to Cancer Therapy, Relapsing-remitting Multiple Sclerosis (RRMS), Metastatic Non-Small Cell Lung Cancer (NSCLC) and Rheumatoid Arthritis. Furthermore, it includes market forecasts for each of the covered therapeutic indications. The report also explores the competitive landscape with a competitive analysis of the top companies in the market.

GBI Research analysis estimated the global monoclonal antibodies market to be valued at $15.6 billion in 2010, with a compound annual growth rate (CAGR) of 36.7% between 2002 and 2010. The market is forecast to grow at a CAGR of 10.6% between 2010 and 2017 and to reach $31.7billion by 2017. In-depth analysis in the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts.

GBI Research analysis found the R&D pipeline for the monoclonal antibodies market to be moderate. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that monoclonal antibodies R&D activity will remain active for at least the next four to five years.

Scope

  • Data and analysis of the monoclonal antibodies market in the leading geographies of the world: the US and Europe. The indications treated by different classes of MAbs discussed, which are covered in this report are in breast cancer, bone loss & metastasis, RRMS, NSCLC and rheumatoid arthritis.
  • Annualized market data for the monoclonal antibodies market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
  • Key drivers and restraints that have had significant impact on the market.
  • Competitive landscape of the global monoclonal antibodies market including benchmarking of the top companies. The key companies analysed in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Eli Lilly

Reasons to buy

  • Build effective strategies to launch pipeline products, by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of the top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global Monoclonal Antibodies market. The report analyzes the markets for monoclonal antibodies in the US, Europe and Rest of the World. Treatment usage patterns, sales, and price are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Monoclonal Antibodies are the Largest Class of Biotherapeutic Drugs

Monoclonal Antibodies (MAbs) were the fastest growing segment in the global pharmaceutical market in 2010. In 2010, the global monoclonal antibodies market was worth $43 billion while the rest of the biologics market was approximately $108 billion. Application of MAbs ranges from various oncology indications to autoimmune diseases. Gradually, MAbs are beginning to pave their way into the treatment of Central Nervous System (CNS) disorders such as Alzheimer's disease and metabolic disorders such as Diabetes. The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab) in 1986. This drug found use in solid organ transplant recipients who became steroid resistant.

Monoclonal Antibodies (MAbs) were the fastest growing segment in the global pharmaceutical market in 2010. In 2010, the global monoclonal antibodies market was worth $43 billion while the rest of the biologics market was approximately $108 billion. Application of MAbs ranges from various oncology indications to autoimmune diseases. Gradually, MAbs are beginning to pave their way into the treatment of Central Nervous System (CNS) disorders such as Alzheimer's disease and metabolic disorders such as Diabetes.

The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab) in 1986. This drug found use in solid organ transplant recipients who became steroid resistant.

Successful MAbs such as Rituxan, Avastin and Remicade have Received Regulatory Approvals for Multiple Indications, which Further Increased the Patient Base

Conventional therapies such as chemotherapies, hormonal therapies and Non-steroidal anti-inflammatory drugs (NSAIDs) have a long history of poor safety profiles due to their systemic-action characteristics. Furthermore, due to their systemic actions, they frequently failed to impart the desired effect at the site of action. These unmet needs propelled researchers to develop MAbs, which specifically target the site of action. Due to this competitive advantage, MAbs are preferred over conventional therapies in disease conditions, which require drug action at specific targets.

The utilization of MAbs increased over the last few years due to increased awareness of these drugs among physicians and patients. New approved MAbs such as Ipilimumab have opened up new patient bases.

Enormous Market Size for MAbs in Diseases Associated With Genetic Mutations Such As Oncology and Autoimmune Diseases

Between 1997 and 2006, the majority of MAbs that received FDA approval were targeted at either cancer indications or autoimmune diseases. These drugs tremendously increased the market size of MAbs. Furthermore, MAbs such as Avastin, Rituxan, and Remicade received follow-on approvals for multiple indications, which have further expanded the market size of MAbs.

After 2006, the majority of MAbs that have received FDA approvals were targeting either niche indications or orphan diseases. This led to the further expansion of MAbs market size.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Monoclonal Antibodies Market to 2017 - Introduction

  • 2.1. GBI Research Report Guidance

3. Monoclonal Antibodies Market to 2017 - Market Characterization

  • 3.1. Introduction
    • 3.1.1. Stability in the Body
    • 3.1.2. Systemic Cancer Treatment
    • 3.1.3. Targeted Therapy
  • 3.2. Monoclonal Antibody Technology
    • 3.2.1. Hybridoma Technology
    • 3.2.2. FuCell Technology
  • 3.3. Revenue Forecasts - Global
    • 3.3.1. Prescription Population
    • 3.3.2. Annual Cost of Therapy
    • 3.3.3. Revenue
  • 3.4. Revenue Forecasts - Countrywise
    • 3.4.1. US
    • 3.4.2. Europe
    • 3.4.3. Rest of the World (ROW)
  • 3.5. Treatment Usage Patterns
    • 3.5.1. The US
    • 3.5.2. Europe
    • 3.5.3. ROW
  • 3.6. Annual Cost of Therapy
    • 3.6.1. The US
    • 3.6.2. Europe
    • 3.6.3. ROW
  • 3.7. Global MAbs Trends
    • 3.7.1. Market Trends
    • 3.7.2. Technology Trends
  • 3.8. Product Trends
    • 3.8.1. Research and Development Focus Shifted Towards Humanized and Fully Human MAbs
  • 3.9. Global MAbs Market Drivers
    • 3.9.1. Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth
    • 3.9.2. Improved Side-effect Profiles and Tolerance of MAbs Therapy
    • 3.9.3. Lack of Effective Conventional Therapies Accelerates Utilization of MAbs
    • 3.9.4. Expanded Indications Opens up New Potential Patient Groups
    • 3.9.5. Lack of Generics Augmented the Sales Growth of MAbs
  • 3.10. Global MAbs Market Restraints
    • 3.10.1. High Cost of MAbs Hampering the Growth of Treatment Population
    • 3.10.2. Adverse Effects - Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy
    • 3.10.3. Industry Challenges - Majority of MAbs Receive Approvals as Last Option Therapies
  • 3.11. Unmet Needs
    • 3.11.1. Reduction in High Cost of MAb Therapies is the Major Unmet Need and it is also Responsible for Low Utilization by Patients
    • 3.11.2. MAbs Do Not Cure Diseases; They either Treat Signs and Symptoms or Decelerate Cell Proliferation

4. Monoclonal Antibodies Market to 2017 - Breast Cancer (Adjuvant and Metastatic)

  • 4.1. Overview
  • 4.2. Introduction
  • 4.3. Prescription Population
    • 4.3.1. Global
    • 4.3.2. The US
    • 4.3.3. Europe
    • 4.3.4. ROW
  • 4.4. Annual Cost of Therapy
    • 4.4.1. Global
    • 4.4.2. The US
    • 4.4.3. Europe
    • 4.4.4. ROW
  • 4.5. Market Size
    • 4.5.1. The US
    • 4.5.2. Europe
    • 4.5.3. ROW
  • 4.6. Marketed Products
    • 4.6.1. Herceptin (trastuzumab)
  • 4.7. Pipeline Analysis
    • 4.7.1. Phase lll
    • 4.7.2. Phase ll
    • 4.7.3. Phase l
    • 4.7.4. Preclinical/Discovery
  • 4.8. Promising Molecules
    • 4.8.1. Pertuzumab (2C4, trade name Omnitarg)
    • 4.8.2. Ramucirumab (IMC-1121B)

5. MAbs Market Size in Bone Metastases and Bone Loss Due to Cancer Therapy

  • 5.1. Introduction
  • 5.2. Epidemiology
  • 5.3. Diagnosis
  • 5.4. Treatment
  • 5.5. Prescription Population
    • 5.5.1. Global
    • 5.5.2. The US
    • 5.5.3. Europe
    • 5.5.4. ROW
  • 5.6. Annual Cost of Therapy
    • 5.6.1. Global
    • 5.6.2. The US
    • 5.6.3. Europe
    • 5.6.4. ROW
  • 5.7. Market Size
    • 5.7.1. Global
    • 5.7.2. The US
    • 5.7.3. Europe
    • 5.7.4. ROW
  • 5.8. Marketed Products
    • 5.8.1. Xgeva (denosumab)
  • 5.9. Pipeline Analysis
    • 5.9.1. NDA Filed
    • 5.9.2. Phase ll
    • 5.9.3. Phase l
    • 5.9.4. Preclinical/Discovery

6. MAbs Market Size in Relapsing-Remitting Multiple Sclerosis (RRMS)

  • 6.1. Introduction
  • 6.2. Epidemiology
  • 6.3. Diagnosis
  • 6.4. Treatment
  • 6.5. Prescription Population
    • 6.5.1. Global
    • 6.5.2. The US
    • 6.5.3. Europe
    • 6.5.4. ROW
  • 6.6. Annual Cost of Therapy
    • 6.6.1. Global
    • 6.6.2. The US
    • 6.6.3. Europe
    • 6.6.4. ROW
  • 6.7. Market Size
    • 6.7.1. Global
    • 6.7.2. The US
    • 6.7.3. Europe
    • 6.7.4. ROW
  • 6.8. Marketed Products
    • 6.8.1. Description
    • 6.8.2. Mechanism of Action
    • 6.8.3. Indications and Usage
    • 6.8.4. Dosage
  • 6.9. Pipeline Analysis
    • 6.9.1. Phase lll
    • 6.9.2. Phase ll
    • 6.9.3. Phase l
    • 6.9.4. Preclinical/Discovery
  • 6.10. Promising Molecules
    • 6.10.1. Campath (Alemtuzumab)
    • 6.10.2. Ocrelizumab

7. MAbs Market Size in Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • 7.1. Introduction
  • 7.2. Epidemiology
  • 7.3. Diagnosis
  • 7.4. Prescription Population
    • 7.4.1. Global
    • 7.4.2. The US
    • 7.4.3. Europe
    • 7.4.4. ROW
  • 7.5. Annual Cost of Therapy
    • 7.5.1. Global
    • 7.5.2. The US
    • 7.5.3. Europe
    • 7.5.4. ROW
  • 7.6. Market Size
    • 7.6.1. Global
    • 7.6.2. The US
    • 7.6.3. Europe
    • 7.6.4. ROW
  • 7.7. Marketed Products
    • 7.7.1. Avastin
  • 7.8. Pipeline Analysis
    • 7.8.1. Phase III
    • 7.8.2. Phase II
    • 7.8.3. Phase I
  • 7.9. Promising Molecule
    • 7.9.1. Necitimumab
    • 7.9.2. Ramucirumab

8. Monoclonal Antibodies Market to 2017 - Rheumatoid Arthritis

  • 8.1. Introduction
  • 8.2. Epidemiology
  • 8.3. Diagnosis
  • 8.4. Treatment
  • 8.5. Prescription Population
    • 8.5.1. Global
    • 8.5.2. The US
    • 8.5.3. Europe
    • 8.5.4. ROW
  • 8.6. Annual Cost of Therapy
    • 8.6.1. Global
    • 8.6.2. The US
    • 8.6.3. Europe
    • 8.6.4. ROW
  • 8.7. Market Size
    • 8.7.1. Global
    • 8.7.2. The US
    • 8.7.3. Europe
    • 8.7.4. ROW
  • 8.8. Marketed Products
    • 8.8.1. Rituxan
    • 8.8.2. Remicade
    • 8.8.3. Humira
    • 8.8.4. Cimzia
    • 8.8.5. Simponi
    • 8.8.6. Actemra
  • 8.9. Pipeline Analysis
    • 8.9.1. Phase III
    • 8.9.2. Phase II
    • 8.9.3. Phase I
    • 8.9.4. Preclinical/ Discovery Phase
  • 8.10. Promising Molecule
    • 8.10.1. Ofatumumab (Arzerra)
    • 8.10.2. SAR153191(REGN88)

9. Monoclonal Antibodies Market to 2017 - Competitive Landscape

  • 9.1. Market Share Analysis
    • 9.1.1. Major Companies
  • 9.2. Amgen Inc.
  • 9.3. Abbott Laboratories
  • 9.4. Johnson & Johnson
  • 9.5. Novartis AG
  • 9.6. Biogen Idec
  • 9.7. Merck & Co. Inc.
    • 9.7.1. Company Profile
    • 9.7.2. Marketed Products
    • 9.7.3. SWOT Analysis
  • 9.8. Eli Lilly and Company
    • 9.8.1. Company Profile
    • 9.8.2. Marketed Products
    • 9.8.3. SWOT Analysis
  • 9.9. Roche
    • 9.9.1. Company Profile
    • 9.9.2. Marketed Products
    • 9.9.3. SWOT Analysis

10. Monoclonal Antibodies Market to 2017 - Strategic Consolidations

  • 10.1. Deal Type
  • 10.2. Mergers & Acquisitions
    • 10.2.1. By Geography
    • 10.2.2. M&A by Year
    • 10.2.3. M&A by Value
    • 10.2.4. Top M&A Deals
  • 10.3. Licensing Agreement
    • 10.3.1. By Geography
    • 10.3.2. By Year
    • 10.3.3. By Value
    • 10.3.4. Licensing Agreement Deals by Value
    • 10.3.5. Top Five Licensing Deals
  • 10.4. Partnerships
    • 10.4.1. By Geography
    • 10.4.2. By Year
    • 10.4.3. By Value

11. Monoclonal Antibodies Market to 2017 - Appendix

  • 11.1. Market Definitions
  • 11.2. Abbreviations
  • 11.3. Research Methodology
    • 11.3.1. Coverage
    • 11.3.2. Secondary Research
    • 11.3.3. Primary Research
    • 11.3.4. Therapeutic Landscape
    • 11.3.5. Geographical Landscape
    • 11.3.6. Pipeline Analysis
    • 11.3.7. Competitive Landscape
    • 11.3.8. Expert Panel Validation
  • 11.4. Contact Us
  • 11.5. Disclaimer
  • 11.6. Sources

List of Tables
  • Table 1: Monoclonal Antibodies Market, Global, Prescription Population (thousands), 2002-2010
  • Table 2: Monoclonal Antibodies Market, Global, Prescription Population, 2010-2017
  • Table 3: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2002-2010
  • Table 4: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2010-2017
  • Table 5: Monoclonal Antibodies Market, Global, Revenue ($bn), 2002-2010
  • Table 6: Monoclonal Antibodies Market, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 7: Monoclonal Antibodies Market, Global, The US, Revenue ($bn), 2002-2010
  • Table 8: Monoclonal Antibodies Market, Global, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 9: Monoclonal Antibodies Market, Global, Europe, Revenue ($bn), 2002-2010
  • Table 10: Monoclonal Antibodies Market, Global, Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 11: Monoclonal Antibodies Market, Global, ROW, Revenue ($bn), 2002-2010
  • Table 12: Monoclonal Antibodies Market, Global, ROW, Revenue Forecasts ($bn), 2010-2017
  • Table 13: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2002- 2010
  • Table 14: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2010- 2017
  • Table 15: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2002- 2010
  • Table 16: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2010- 2017
  • Table 17: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2002- 2010
  • Table 18: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2010- 2017
  • Table 19: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2002- 2010
  • Table 20: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2010- 2017
  • Table 21: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2002- 2010
  • Table 22: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2010- 2017
  • Table 23: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2002- 2010
  • Table 24: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2010- 2017
  • Table 25: Monoclonal Antibodies Market, Breast Cancer, Global, Prescription Population, 2002- 2010
  • Table 26: Monoclonal Antibodies Market, Breast Cancer, Global, Prescription Population, 2010- 2017
  • Table 27: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2002- 2010
  • Table 28: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2010- 2017
  • Table 29: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2002- 2010
  • Table 30: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2010- 2017
  • Table 31: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2002- 2010
  • Table 32: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2010- 2017
  • Table 33: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2002- 2010
  • Table 34: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2010- 2017
  • Table 35: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2002- 2010
  • Table 36: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2010- 2017
  • Table 37: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2002- 2010
  • Table 38: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2010- 2017
  • Table 39: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2002- 2010
  • Table 40: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2010- 2017
  • Table 41: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue ($bn), 2002- 2010
  • Table 42: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue Forecasts ($bn), 2010- 2017
  • Table 43: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue ($bn), 2002- 2010
  • Table 44: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue Forecasts ($bn), 2010- 2017
  • Table 45: Monoclonal Antibodies Market, Breast Cancer, Europe, Revenue ($bn), 2002- 2010
  • Table 46: Monoclonal Antibodies Market, Breast Cancer, Europe, Revenue Forecasts ($bn), 2010- 2017
  • Table 47: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue ($bn), 2002- 2010
  • Table 48: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue Forecasts ($bn), 2010- 2017
  • Table 49: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase lll Molecules, 2011
  • Table 50: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase ll Molecules, 2011
  • Table 51: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase l Molecules, 2011
  • Table 52: Monoclonal Antibodies Market, HER2 Breast Cancer, Preclinical/Discovery Molecules, 2011
  • Table 53: Monoclonal Antibodies Market, Bone Metastasis, Global, Prescription Population, 2011- 2017
  • Table 54: Monoclonal Antibodies Market, Bone Metastasis, the US, Prescription Population, 2011- 2017
  • Table 55: Monoclonal Antibodies Market, Bone Metastasis, Europe, Prescription Population, 2011- 2017
  • Table 56: Monoclonal Antibodies Market, Bone Metastasis, ROW, Prescription Population, 2011- 2017
  • Table 57: Monoclonal Antibodies Market, Bone Metastasis, Global, Annual Cost of Therapy ($), 2011- 2017
  • Table 58: Monoclonal Antibodies Market, Bone Metastasis,The US, Annual Cost of Therapy ($), 2011- 2017
  • Table 59: Monoclonal Antibodies Market, Bone Metastasis,Europe, Annual Cost of Therapy, 2011- 2017
  • Table 60: Monoclonal Antibodies Market, Bone Metastasis, ROW, Annual Cost of Therapy ($), 2011- 2017
  • Table 61: Monoclonal Antibodies Market, Bone Metastasis, Global, Revenue Forecasts ($bn), 2011- 2017
  • Table 62: Monoclonal Antibodies Market, Bone Metastasis,The US, Revenue Forecasts ($m), 2011- 2017
  • Table 63: Monoclonal Antibodies Market, Bone Metastasis, Europe, Revenue Forecasts ($m), 2011- 2017
  • Table 64: Monoclonal Antibodies Market, Bone Metastasis, ROW, Revenue Forecasts ($m), 2011- 2017
  • Table 65: Monoclonal Antibodies Market, Bone Metastasis, NDA Filed Molecules , 2011
  • Table 66: Monoclonal Antibodies Market, Bone Metastasis, Phase ll Molecules , 2011
  • Table 67: Monoclonal Antibodies Market, Bone Metastasis, Phase l Molecules , 2011
  • Table 68: Monoclonal Antibodies Market, Bone Metastasis, Preclinical/Discovery Molecules , 2011
  • Table 69: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2006- 2010
  • Table 70: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2010- 2017
  • Table 71: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2006- 2010
  • Table 72: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2010- 2017
  • Table 73: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2006- 2010
  • Table 74: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2010- 2017
  • Table 75: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2009- 2010
  • Table 76: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2010- 2017
  • Table 77: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2006- 2010
  • Table 78: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2010- 2017
  • Table 79: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2006- 2010
  • Table 80: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2010- 2017
  • Table 81: Monoclonal Antibodies Market, RRMS,Europe, Annual Cost of Therapy ($), 2006 2010
  • Table 82: Monoclonal Antibodies Market, RRMS,Europe, Annual Cost of Therapy ($), 2010- 2017
  • Table 83: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2006- 2010
  • Table 84: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2010- 2017
  • Table 85: Monoclonal Antibodies Market, RRMS, Global, Revenue ($bn), 2006- 2010
  • Table 86: Monoclonal Antibodies Market, RRMS, Global, Revenue Forecasts ($bn), 2010- 2017
  • Table 87: Monoclonal Antibodies Market, RRMS,The US, Revenue ($m), 2006- 2010
  • Table 88: Monoclonal Antibodies Market, RRMS,The US, Revenue Forecasts ($m), 2010- 2017
  • Table 89: Monoclonal Antibodies Market, RRMS,Europe, Revenue ($m), 2006- 2010
  • Table 90: Monoclonal Antibodies Market, RRMS,Europe, Revenue Forecasts ($m), 2010- 2017
  • Table 91: Monoclonal Antibodies Market, RRMS, ROW, Revenue ($m), 2009- 2010
  • Table 92: Monoclonal Antibodies Market, RRMS, ROW, Revenue Forecasts ($m), 2010- 2017
  • Table 93: Monoclonal Antibodies Market, RRMS, Phase lll Molecules, 2011
  • Table 94: Monoclonal Antibodies Market, RRMS, Phase ll Molecules, 2011
  • Table 95: Monoclonal Antibodies Market, RRMS, Phase l Molecules, 2011
  • Table 96: Monoclonal Antibodies Market, RRMS, Preclinical/Discovery Molecules, 2011
  • Table 97: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2007- 2010
  • Table 98: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2010- 2017
  • Table 99: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2007- 2010
  • Table 100: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2010- 2017
  • Table 101: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2008- 2010
  • Table 102: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2010- 2017
  • Table 103: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2007- 2010
  • Table 104: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2010- 2017
  • Table 105: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2007- 2010
  • Table 106: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2010- 2017
  • Table 107: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2007- 2010
  • Table 108: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2010- 2017
  • Table 109: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2008- 2010
  • Table 110: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2010- 2017
  • Table 111: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2007- 2010
  • Table 112: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2010- 2017
  • Table 113: Monoclonal Antibodies Market, NSCLC, Global, Revenue ($bn), 2007- 2010
  • Table 114: Monoclonal Antibodies Market, NSCLC, Global, Revenue Forecasts ($bn), 2010- 2017
  • Table 115: Monoclonal Antibodies Market, NSCLC, The US, Revenue ($bn), 2007- 2010
  • Table 116: Monoclonal Antibodies Market, NSCLC, The US, Revenue Forecasts ($bn), 2010- 2017
  • Table 117: Monoclonal Antibodies Market, NSCLC, Europe, Revenue ($million), 2008- 2010
  • Table 118: Monoclonal Antibodies Market, NSCLC, Europe, Revenue Forecasts ($million), 2010- 2017
  • Table 119: Monoclonal Antibodies Market, NSCLC, ROW, Revenue ($m), 2007- 2010
  • Table 120: Monoclonal Antibodies Market, NSCLC, ROW, Revenue Forecasts ($m), 2010- 2017
  • Table 121: Monoclonal Antibodies Market, NSCLC, Phase lll Molecules, 2011
  • Table 122: Monoclonal Antibodies Market, NSCLC, Phase ll Molecules, 2011
  • Table 123: Monoclonal Antibodies Market, NSCLC, Phase l Molecules, 2011
  • Table 124: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2002- 2010
  • Table 125: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2010- 2017
  • Table 126: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2002- 2010
  • Table 127: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2010- 2017
  • Table 128: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2002- 2010
  • Table 129: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2010- 2017
  • Table 130: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2002- 2010
  • Table 131: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2010- 2017
  • Table 132: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2002- 2010
  • Table 133: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2010- 2017
  • Table 134: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2002- 2010
  • Table 135: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2010- 2017
  • Table 136: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2002- 2010
  • Table 137: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2010- 2017
  • Table 138: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2002- 2010
  • Table 139: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2010- 2017
  • Table 140: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue ($bn), 2002- 2010
  • Table 141: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue Forecasts ($bn), 2010- 2017
  • Table 142: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue ($bn), 2002- 2010
  • Table 143: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue Forecasts ($bn), 2010- 2017
  • Table 144: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue ($m), 2002- 2010
  • Table 145: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue ($m), 2002- 2010
  • Table 146: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue ($bn), 2002- 2010
  • Table 147: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue Forecasts ($bn), 2010- 2017
  • Table 148: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase III Molecules, 2011
  • Table 149: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase II Molecules, 2011
  • Table 150: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase I Molecules, 2011
  • Table 151: Monoclonal Antibodies Market, Rheumatoid Arthritis, Preclinical/ Discovery Phase Molecules, 2011
  • Table 152: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
  • Table 153: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
  • Table 154: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
  • Table 155: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
  • Table 156: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
  • Table 157: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010
  • Table 158: Monoclonal Antibodies Market, Strategic Consolidations, Top M&A Deals, 2011
  • Table 159: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement Deals by Value, 2011
  • Table 160: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Value, 2011

List of Figures
  • Figure 1: Monoclonal Antibodies Market, Global, Drivers and Barriers, 2011
  • Figure 2: Monoclonal Antibodies Market, Global, Prescription Population (thousands), 2002-2017
  • Figure 3: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2002-2017
  • Figure 4: Monoclonal Antibodies Market, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 5: Monoclonal Antibodies Market, Global, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 6: Monoclonal Antibodies Market, Global, Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 7: Monoclonal Antibodies Market, Global, ROW, Revenue Forecasts ($bn), 2002-2017
  • Figure 8: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2002- 2017
  • Figure 9: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2002- 2017
  • Figure 10: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2002- 2017
  • Figure 11: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2002- 2017
  • Figure 12: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2002- 2017
  • Figure 13: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2002- 2017
  • Figure 14: Monoclonal Antibodies Market, Global, Revenue Distibution by Indication (%), 2011
  • Figure 15: Monoclonal Antibodies Market, Breast Cancer,Global, Prescription Population, 2002- 2017
  • Figure 16: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2002- 2017
  • Figure 17: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2002- 2017
  • Figure 18: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2002- 2017
  • Figure 19: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2002- 2017
  • Figure 20: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2002- 2017
  • Figure 21: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2002- 2017
  • Figure 22: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2002- 2017
  • Figure 23: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue Forecasts ($bn), 2002- 2017
  • Figure 24: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue Forecasts ($bn), 2002- 2017
  • Figure 25: Monoclonal Antibodies Market, Breast Cancer,Europe, Revenue Forecasts ($bn), 2002- 2017
  • Figure 26: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue Forecasts ($bn), 2002- 2017
  • Figure 27: Monoclonal Antibodies Market, HER2 Breast Cancer, Pipeline Analysis (%), 2011
  • Figure 28: Monoclonal Antibodies Market, Bone Metastasis, Global, Prescription Population, 2011- 2017
  • Figure 29: Monoclonal Antibodies Market, Bone Metastasis, the US, Prescription Population, 2011- 2017
  • Figure 30: Monoclonal Antibodies Market, Bone Metastasis, Europe, Prescription Population, 2011- 2017
  • Figure 31: Monoclonal Antibodies Market, Bone Metastasis, ROW, Prescription Population, 2011- 2017
  • Figure 32: Monoclonal Antibodies Market, Bone Metastasis, Global, Annual Cost of Therapy ($), 2011- 2017
  • Figure 33: Monoclonal Antibodies Market, Bone Metastasis,The US, Annual Cost of Therapy ($), 2011- 2017
  • Figure 34: Monoclonal Antibodies Market, Bone Metastasis,Europe, Annual Cost of Therapy, 2011- 2017
  • Figure 35: Monoclonal Antibodies Market, Bone Metastasis, ROW, Annual Cost of Therapy ($), 2011- 2017
  • Figure 36: Monoclonal Antibodies Market, Bone Metastasis, Global, Revenue Forecasts ($bn), 2011- 2017
  • Figure 37: Monoclonal Antibodies Market, Bone Metastasis,The US, Revenue Forecasts ($m), 2011- 2017
  • Figure 38: Monoclonal Antibodies Market, Bone Metastasis,Europe, Revenue Forecasts ($m), 2011- 2017
  • Figure 39: Monoclonal Antibodies Market, Bone Metastasis, ROW, Revenue Forecasts ($m), 2011- 2017
  • Figure 40: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2006- 2017
  • Figure 41: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2006- 2017
  • Figure 42: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2006- 2017
  • Figure 43: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2009- 2017
  • Figure 44: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2006- 2017
  • Figure 45: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2006- 2017
  • Figure 46: Monoclonal Antibodies Market, RRMS, Europe, Annual Cost of Therapy ($), 2006- 2017
  • Figure 47: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2006- 2017
  • Figure 48: Monoclonal Antibodies Market, RRMS, Global, Revenue Forecasts ($bn), 2006- 2017
  • Figure 49: Monoclonal Antibodies Market, RRMS,The US, Revenue Forecasts ($m), 2006- 2017
  • Figure 50: Monoclonal Antibodies Market, RRMS,Europe, Revenue Forecasts ($m), 2006- 2017
  • Figure 51: Monoclonal Antibodies Market, RRMS, ROW, Revenue Forecasts ($m), 2009- 2017
  • Figure 52: Monoclonal Antibodies Market, RRMS, Pipeline Analysis, (%), 2011
  • Figure 53: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2007- 2017
  • Figure 54: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2007- 2017
  • Figure 55: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2008- 2017
  • Figure 56: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2007 2017
  • Figure 57: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2007- 2017
  • Figure 58: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2007- 2017
  • Figure 59: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2008- 2017
  • Figure 60: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2007- 2017
  • Figure 61: Monoclonal Antibodies Market, NSCLC, Global, Revenue Forecasts ($bn), 2007- 2017
  • Figure 62: Monoclonal Antibodies Market, NSCLC, The US, Revenue Forecasts ($bn), 2007- 2017
  • Figure 63: Monoclonal Antibodies Market, NSCLC, Europe, Revenue Forecasts ($million), 2008- 2017
  • Figure 64: Monoclonal Antibodies Market, NSCLC, ROW, Revenue Forecasts ($m), 2007- 2017
  • Figure 65: Monoclonal Antibodies Market, NSCLC, Pipeline Analysis, (%), 2011
  • Figure 66: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2002- 2017
  • Figure 67: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2002- 2017
  • Figure 68: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2002- 2017
  • Figure 69: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2002- 2017
  • Figure 70: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2002- 2017
  • Figure 71: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2002- 2017
  • Figure 72: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2002- 2017
  • Figure 73: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2002- 2017
  • Figure 74: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue Forecasts ($bn), 2002- 2017
  • Figure 75: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue Forecasts ($bn), 2002- 2017
  • Figure 76: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue Forecasts ($bn), 2002- 2017
  • Figure 77: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue Forecasts ($bn), 2002- 2017
  • Figure 78: Monoclonal Antibodies Market, Rheumatoid Arthritis, Pipeline Analysis, (%), 2011
  • Figure 79: Monoclonal Antibodies Market to 2017, Global, Market share Analysis by Company (%), 2010
  • Figure 80: Monoclonal Antibodies Market to 2017, Amgen Inc SWOT Analysis, 2011
  • Figure 81: Monoclonal Antibodies Market to 2017, Abbott Laboratories SWOT Analysis, 2011
  • Figure 82: Monoclonal Antibodies Market to 2017, Johnson & Johnson SWOT Analysis, 2011
  • Figure 83: Monoclonal Antibodies Market to 2017, Novartis AG SWOT Analysis, 2011
  • Figure 84: Monoclonal Antibodies Market to 2017, Biogen Idec SWOT Analysis, 2011
  • Figure 85: Monoclonal Antibodies Market to 2017, Merck & Co Inc SWOT Analysis, 2011
  • Figure 86: Monoclonal Antibodies Market to 2017, Eli Lilly and Company SWOT Analysis, 2011
  • Figure 87: Monoclonal Antibodies Market to 2017, Roche SWOT Analysis, 2011
  • Figure 88: Monoclonal Antibodies Market, Strategic Consolidations, Analysis by Deal Type, 2010-2011
  • Figure 89: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Geography, 2011
  • Figure 90: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Year, 2011
  • Figure 91: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Value, 2011
  • Figure 92: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Geography, 2011
  • Figure 93: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Year, 2011
  • Figure 94: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Value, 2011
  • Figure 95: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Geography, 2011
  • Figure 96: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Year, 2011
  • Figure 97: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Value, 2011
  • Figure 98: GBI Research Market Forecasting Model
Back to Top